Literature DB >> 22321466

Management of overt hepatic encephalopathy.

Vandana Khungar1, Fred Poordad.   

Abstract

Hepatic encephalopathy (HE) is a potentially reversible state of impaired cognitive function or altered consciousness in patients with liver disease or portosystemic shunting. Overt HE is a particularly pressing problem. Given the many targets of treatment and lack of a clear singular cause of overt HE, there is no consensus on a single best treatment. Over the past several years, high-quality studies have been conducted on the various pharmacologic therapies for HE and, as more data emerge, hopefully HE will become a much more easily treated complication of decompensated liver disease.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22321466     DOI: 10.1016/j.cld.2011.12.007

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  4 in total

Review 1.  Advances in cirrhosis: Optimizing the management of hepatic encephalopathy.

Authors:  Andy Liu; Ryan B Perumpail; Radhika Kumari; Zobair M Younossi; Robert J Wong; Aijaz Ahmed
Journal:  World J Hepatol       Date:  2015-12-18

Review 2.  Hepatic Encephalopathy and Melatonin.

Authors:  Archana Arjunan; Dhiraj Kumar Sah; Young Do Jung; Juhyun Song
Journal:  Antioxidants (Basel)       Date:  2022-04-25

3.  Application of tabu search-based Bayesian networks in exploring related factors of liver cirrhosis complicated with hepatic encephalopathy and disease identification.

Authors:  Zhuang Zhang; Jie Zhang; Zhen Wei; Hao Ren; Weimei Song; Jinhua Pan; Jinchun Liu; Yanbo Zhang; Lixia Qiu
Journal:  Sci Rep       Date:  2019-04-18       Impact factor: 4.379

4.  Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis.

Authors:  Zhaohui Bai; Mauro Bernardi; Eric M Yoshida; Hongyu Li; Xiaozhong Guo; Nahum Méndez-Sánchez; Yingying Li; Ran Wang; Jiao Deng; Xingshun Qi
Journal:  Aging (Albany NY)       Date:  2019-10-08       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.